Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: October 31, 2004
Business Overview: Cooper operates two primary segments: CooperVision (CVI), a global manufacturer of soft contact lenses specializing in specialty segments (toric, cosmetic, multifocal), and CooperSurgical (CSI), a provider of medical devices and surgical instruments for women's healthcare (Ob/Gyn). The company is headquartered in Pleasanton, California.
Key Financial Metrics
| Metric | Fiscal 2004 | Fiscal 2003 | Change |
|---|---|---|---|
| Net Sales | $490.2 million | $411.8 million | +19% |
| Gross Profit | $315.8 million | $265.2 million | +19% |
| Gross Margin | 64.4% | 64.4% | 0% |
| Operating Income | $116.8 million | $95.2 million | +23% |
| Operating Margin | 23.8% | 23.1% | +0.7 pts |
| Net Income | $92.8 million | $68.8 million | +35% |
| Diluted EPS | $2.59 | $2.09 | +24% |
| Operating Cash Flow | $101.2 million | $79.6 million | +27% |
| Total Debt | $165.7 million | $185.9 million | -11% |
| Stockholders' Equity | $544.2 million | $422.0 million | +29% |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated sales grew 19% driven by double-digit growth in both segments. CVI revenue increased 18% (U.S. +12%, International +24%), while CSI revenue rose 23% to $101.5 million.
- Profitability: Operating income increased 23% to $116.8 million. The effective tax rate decreased significantly to 17.5% from 24.0% in 2003, attributed to a higher percentage of income taxed at lower foreign rates and the release of tax reserves.
- Acquisitions: The company completed four acquisitions in fiscal 2004 (Opti-Centre, Argus, Milex, and SURx assets) totaling $63.9 million in cash outflows. These acquisitions contributed to CSI's revenue growth.
- Debt Reduction: Total debt decreased by $20.2 million due to strong operating cash flows and the repayment of revolving credit facilities.
Guidance, Outlook, and Risks
Outlook and Guidance
- CVI Outlook: Management expects CVI revenue growth to outpace the anticipated constant currency market increase of 8-10%.
- CSI Guidance: Fiscal 2005 revenue for CSI is expected to range between $115 million and $118 million.
- Tax Rate: The company expects an effective tax rate of approximately 21% for fiscal 2005.
Subsequent Events
- Ocular Sciences Acquisition: On January 6, 2005, Cooper acquired Ocular Sciences, Inc. for approximately $1.2 billion (cash and stock). This transaction significantly expands Cooper's presence in the daily disposable and spherical lens markets.
- Financing: Concurrent with the Ocular acquisition, Cooper replaced its existing credit facility with a new $750 million credit agreement.
Risks and Contingencies
- Integration Risk: Risks associated with the successful integration of the Ocular Sciences business and other recent acquisitions.
- Regulatory: Dependence on FDA and foreign regulatory approvals for new products; potential for product recalls.
- Accounting Changes: Adoption of FASB Statement No. 123(R) regarding share-based payment is expected to impact net income and EPS starting in fiscal 2005.
- Market Risk: Exposure to foreign currency fluctuations and interest rate changes, though hedging strategies are in place.
Investor Verification Checklist
- Ocular Sciences Integration: Verify the progress of integrating Ocular Sciences' operations and the realization of anticipated synergies post-acquisition.
- Effective Tax Rate: Monitor the sustainability of the low effective tax rate (17.5%) and the utilization of U.S. net operating loss carryforwards.
- Debt Covenants: Review compliance with the new $750 million credit facility covenants, specifically the debt-to-capitalization and EBITDA ratios.
- Stock-Based Compensation: Assess the impact of the new FASB 123(R) standard on future earnings per share.
- Goodwill Valuation: Monitor the $913.9 million goodwill assigned to the Ocular acquisition and future impairment testing results.